MedTrace Logo

Evaluating an Innovative HIV Self-testing Service With Counseling Provided by a Chatbot

NCT05796622 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 564

Last updated 2023-04-03

No results posted yet for this study

Summary

A parallel-group non-inferiority randomized controlled trial will then be conducted to evaluate the performance of HIVST-Chatbot. A total of 528 Hong Kong Chinese speaking men who have sex with men (MSM) aged ≥18 years who have access to live-chat applications are recruited from multiple sources. Those who are diagnosed as HIV positive are excluded. Participants are 1:1 randomized into the intervention group (n=264) or the control group (n=264). The research team will implement the HIVST-Chatbot (HIVST services with real-time counselling provided by a fully-automated artificial intelligence Chatbot) in the intervention group and HIVST-OIC (HIVST with real-time counselling provided by trained administrators) in the control group. Participants completed two telephone surveys at baseline and six months afterwards.

Conditions

  • Behaviors, Health

Interventions

BEHAVIORAL

HIVST-Chatbot (HIV self-testing services with counseling provided by a Chatbot)

Promote and implement HIVST-Chatbot

BEHAVIORAL

HIVST-OIC (HIV self-testing services with counseling provided by administrators)

Promote and implement HIVST-OIC

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Zixin Wang, PhD · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-16
Primary Completion
2024-02-28
Completion
2024-02-28

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05796622 on ClinicalTrials.gov